VYNE Therapeutics

Therapies for the Treatment of Immuno-inflammatory Conditions

Health Tech & Life Sciences
Acquired (Inactive) by Menlo Therapeutics on Nov 2019 - ceased to operate

Company Overview

Snapshot

Founded in January 2003 by Meir Eini, VYNE Therapeutics operates with 51–200 employees. The company has raised $180M across 4 funding rounds from 2 investors. In November 2019, the company was acquired by Menlo Therapeutics, ceasing independent operations.

Business overview

VYNE Therapeutics is a biopharmaceutical company dedicated to developing proprietary and differentiated therapies for immuno-inflammatory conditions. The company leverages its Molecule Stabilizing Technology to create solutions, including the FDA-approved AMZEEQ (minocycline) topical foam, 4% for acne, and ZILXI (minocycline) topical foam, 1.5% for rosacea. It serves the dermatology and pharmaceutical markets, operating within the Health Tech & Life Sciences sector.

Strategic signal

In November 2022, VYNE Therapeutics announced the first subjects were dosed in a Phase 1a/b clinical trial evaluating its Pan-BET Inhibitor, VYN201, for the treatment of Vitiligo. This signals the company's continued commitment to advancing its pipeline and exploring new therapeutic areas beyond its existing dermatology products, indicating potential for future growth and market expansion.

Company Intelligence Q&A

What was a significant corporate event for VYNE Therapeutics in late 2019?
In November 2019, VYNE Therapeutics was acquired by Menlo Therapeutics, leading to the cessation of its independent operations.
When did VYNE Therapeutics change its name?
In September 2020, Menlo Therapeutics completed its corporate name change to VYNE Therapeutics.
What was a key product launch for VYNE Therapeutics in late 2020?
In October 2020, VYNE Therapeutics announced that ZILXI™ (minocycline) topical foam, 1.5% became available in pharmacies nationwide.
What clinical trial progress did VYNE Therapeutics announce in early 2023?
In January 2023, VYNE Therapeutics announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of its novel BET Inhibitor VYN201.
What intellectual property milestone did VYNE Therapeutics achieve in late 2022?
In December 2022, VYNE Therapeutics announced the first patent granted for its novel BET Inhibitor Platform.

External links